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The  goal  of  the  present  study  was  to evaluate  the  inﬂuence  of  the  inﬂuenza  A  H1N1/2009  vaccine  on der-
matomyositis/polymyositis  (DM/PM)  disease  parameters  and  the  potential  deleterious  effect  of therapy
on  immune  response.  Thirty-seven  DM  and  21  PM patients  (Bohan  and  Peter’s  criteria)  were  gender-  and
age-matched  to  116  healthy  controls.  Seroprotection,  seroconversion,  the  geometric  mean  titers  (GMTs)
and  the  factor  increase  (FI)  in  the  GMTs  were  calculated.  Disease  safety  was  determined  from  a  muscle
enzyme  analysis  and  the  DM/PM  scores  [patient’s  visual  analog  scale  (VAS),  physician’s  VAS,  manual
muscle  strength  (MMT-8)]  evaluated  pre-  and  post-vaccination.  The  mean  age  (43.1  ±  9.9  vs.  43.8 ± 8.4
years,  p  =  0.607)  and  gender  distribution  (p = 1.00)  were  comparable  between  the  patients  and  controls.
After  21  days,  seroconversion  (p  =  0.394),  seroprotection  (p  = 0.08),  GMT  (p  =  0.573)  and  the  FI  in the GMT
(p  =  0.496)  were  similar  in  both  groups.  The  disease  and  muscle  parameters  remained  stable  through-
out  the  study,  including  the  creatine  kinase  (p  =  0.20)  and  aldolase  levels  (p =  0.98),  the  physicians’  VAS
(p  =  1.00),  the  patients’  VAS  (p =  1.00)  and  the  MMT-8  (p  =  1.00).  Regarding  the  inﬂuence  of  treatment,  the
seroconversion  rates  were  comparable  between  the  controls  and  patients  undergoing  treatment  with
glucocorticoid  (GC)  (p =  0.969),  GC  >0.5 mg/kg/day  (p = 0.395)  and  GC +  immunosuppressors  (p  = 0.285).
Vaccine-related  adverse  events  were  mild  and  similar  in  the  DM/PM  and  control  groups  (p > 0.05).  Our
data  support  the  administration  of  the  pandemic  inﬂuenza  A  H1N1/2009  vaccination  in  DM/PM,  as  we
found  no short-term  harmful  effects  related  to  the  disease  itself  and  adequate  immunogenicity  in spite
of  therapy.  Further  studies  are  necessary  to identify  any  long-term  adverse  effects  in patients  with  these
diseases.. Introduction
The pandemic inﬂuenza A (H1N1) emerged and rapidly spread
orldwide in 2009, affecting mainly young population [1]. Its
pectrum of clinical presentation varied from asymptomatic to
espiratory failure and death [2]. Serious outcomes of inﬂuenza
isease have been associated with risk factors such as underlying
edical conditions, including obesity, pregnancy, cardiovascular
 ClinicalTrials.gov number: NCT01151644.
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diseases and immunosuppressive therapy [3]. Impairment of
immune function inherent to the disease itself or secondary
to drugs seems to underlie the higher risk in patients under
immunosuppressant treatment [4], supporting the recent recom-
mendations of the Advisory Committee on Immunization Practices
and the European League Against Rheumatism that immunocom-
promised patients should receive the ﬂu vaccine [5,6].
The  efﬁcacy and safety of vaccination with the monovalent pan-
demic adjuvanted H1N1 inﬂuenza were demonstrated by Elkayam
et al. [7] and Gabay et al. [8] in a limited number of patients
with rheumatic diseases. Previous seasonal vaccine studies did not
include patients with idiopathic inﬂammatory myopathies, and
evaluations of the safety of vaccines against other microbial agents
Open access under the Elsevier OA license.for these patients are also scarce [9–13]. Another uncertain topic is
the potential risk of ﬂares of DM/PM following vaccination.
More recently, we reported the overall short-term safety,
but reduced immunogenicity, of an adjuvant-free inﬂuenza A
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H1N1) vaccine in a cohort of 1668 autoimmune rheumatic dis-
ase patients, including for the ﬁrst time 73 dermatomyositis
DM)/polymyositis (PM) patients [14]. However, the vaccine’s
otential deleterious effects on the disease parameters and the pos-
ible inﬂuence of therapy on the vaccine antibody response have
ot been explored.
Therefore, the objectives of the present study were to evaluate
he inﬂuence of inﬂuenza A H1N1/2009 vaccine in DM/PM disease
arameters and the potential deleterious effect of therapy on the
mmunoresponse.
. Materials and methods
.1.  Study design and participants
The  present study was prospective and was conducted at a single
enter during the Public National Health pandemic 2009 inﬂuenza
 (H1N1) vaccination campaign in Brazil. It was  approved by the
nstitutional review board of our university hospital and registered
t ClinicalTrials.gov number: NCT01151644. The study included
wo stages: vaccination (March 22nd to April 2nd, 2010) and a
ollow-up period of 21 days with a personal diary card for reporting
dverse events.
Out  of 73 adult DM/PM patients (Bohan and Peter’s criteria)
15] who received the vaccination and regularly attended at the
diopathic Inﬂammatory Myopathies Outpatient Clinics, 58 adult
atients (37 DM and 21 PM)  had complete serology, clinical and
herapeutic data and were included in the study. Out of 234 healthy
accinated individuals recruited from the hospital’s immunization
enter, 116 gender- and age-matched individuals were randomly
elected as controls.
.2.  Exclusion criteria
The  exclusion criteria were a previous known infection with
andemic 2009 inﬂuenza A H1N1; a history of anaphylactic
esponse to vaccine components or to eggs; an acute infection
esulting in a fever of over 38 ◦C at the time of vaccination; a history
f Guillain–Barré syndrome or demyelination syndromes, cancer,
r other associated autoimmune diseases; vaccination with any
ive vaccine within a period of 4 weeks prior to the study, any
nactivated vaccine within a period of 2 weeks prior to the study, or
he 2010 seasonal inﬂuenza vaccine; a blood transfusion within a
eriod of 6 months prior to the study; less than 8 weeks of anti-TNF
herapy, hospitalization during the study; or failure to complete the
rotocol [14].
.3.  Vaccine
The vaccine, Sanoﬁ Pasteur 2009 inﬂuenza A (H1N1) was a novel
onovalent adjuvant-free vaccine (A/California/7/2009/Butantan
nstitute/Sanoﬁ Pasteur). The active component was a split inactiv-
ted inﬂuenza virus containing 15 g hemagglutinin (HA) from an
nﬂuenza A/California/07/2009 (H1N1) virus-like strain (NYMCx-
79A) per 0.5 mL  dose [9]. It was available as 5 mL  multidose vials
ith thimerosal (45 g/0.5 mL  dose) added as preservative and was
tored at 2–8 ◦C until used.
.4.  Study procedures
All  subjects were vaccinated with a single intramuscular dose
deltoid muscle) of the H1N1 vaccine using a 22Gx1.¼ in. needle.
he patient’s visual analog score (VAS) and physician’s VAS [16,17],
he manual muscle testing score (MMT-8) [18,19], and the blood
ample collection were assessed before and 21 days after the vac-
ination. Muscle enzymes were determined using an automated31 (2012) 202– 206 203
kinetic  method [creatine kinase (normal range: 24–173 IU/L) and
aldolase (normal range: 1.0–7.5 IU/L)].
2.5. Safety assessments
A  21-day symptom diary-card for prospective completion was
given to each participant following vaccination and returned 21
days later. All new symptoms, recorded or not, in the diary were
reviewed by the investigators, and the causal relationship with the
vaccine was  assessed. All patients answered one speciﬁc (yes or no)
question about their perception of the vaccine’s interference with
their disease activity. Local reactions were deﬁned as local pain,
redness, swelling and itching, whereas systemic reactions included
arthralgia, fever, headache, myalgia, sore throat, cough, diarrhea,
rhinorrhea and nasal congestion.
2.6.  Laboratory assays
The  immunogenicity of the H1N1 A/California/7/2009-like virus
vaccine was  evaluated (hemagglutination inhibition assay-HIA) at
Adolfo Lutz Institute [13]. The antibody titers were assessed at
baseline and 21 days post-immunization. The following serologic
endpoints were evaluated: the seroprotection rate, deﬁned as the
percentage of patients with a titer ≥1:40, and the seroconversion
rate, deﬁned as the percentage of patients with a ≥fourfold increase
in vaccination titer if the pre-vaccination titer was ≥1:10 or a post-
vaccination titer ≥1:40 if the pre-vaccination titer was <1:10.
2.7.  Statistical analysis
Two-sided  95% conﬁdence intervals (CI) were calculated assum-
ing binomial distributions for dichotomous variables and a
log-normal distribution for hemagglutination inhibition titers.
For the categorical variables, the statistical summaries included
the rates of seroconversion and seroprotection; these rates were
compared using Fisher’s exact test. For every subgroup, the
hemagglutination inhibition geometric mean titers (GMTs) were
calculated before vaccination and 21 days after vaccination. The
factor increase in the GMTs (i.e., the ratio of the titers after vac-
cination to the titers before vaccination) was also obtained. The
factor increases and the GMTs were compared between DM/PM
patients and controls using Student’s two-sided t-test with the log-
transformed titers. The Wilcoxon signed rank test was performed
to analyze paired and non-parametric data.
3. Results
3.1. Demographic characteristics
The  mean current age was  comparable in the DM/PM patients
and controls (43.1 ± 9.9 vs. 43.8 ± 8.4 years, p = 0.607), with a similar
frequency (75.9%) of female gender in both groups (p = 1.00). The
disease duration was  7.3 ± 6.3 years.
3.2.  The inﬂuence of the vaccine on disease parameters
Table 1 illustrates the DM/PM parameters and treatment status
before and after the inﬂuenza A H1N1/2009 vaccination. The pre-
and post-vaccination disease and muscle parameters were com-
parable [patients’ VAS (p = 1.00), physicians’ VAS (p = 1.00), MMT-8
(p = 1.00), creatine kinase (p = 0.19) and aldolase (p = 0.98)].
Glucocorticoid and immunosuppressive treatments remained
unchanged throughout the study (p > 0.05), as shown in Table 1.
The frequencies of the use of immunosuppressive therapy were
as follows: methotrexate (39.7%), azathioprine (32.8%), chloro-
quine diphosphate (15.5%), cyclosporine (13.8%), mycophenolate
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Table  1
Dermatomyositis/polymyositis parameters and treatment before and after inﬂuenza A H1N1/2009 vaccine.
Variables (reference values) Pre-vaccination (n = 58) Post-vaccination (n = 58) p
DM/PM parameters
Patient’s VAS (0–10) 0 [0–1] 0 [0–1] 1.000
Physician’s  VAS (0–10) 0 [0–1] 0 [0–1] 1.000
MMT-8  (0–80) 80 [80] 80 [80] 0.500
Creatine  kinase, IU/L (24–173) 145.5 [121–186] 167.5 [98–321] 0.200
Aldolase,  IU/L (1.0–7.5) 4.6 [3.6–5.5] 4.4 [3.4–7.7] 0.980
Treatment
Prednisone
Current  use 32 (55.2)  32 (55.2) 1.000
Dose,  mg/day 9.7  (2.5–60) 9.7 (2.5–60) 1.000
Prednisone  ≥0.5 mg/kg/day 9 (15.5) 9 (15.5) 1.000
Methotrexate
Current  use 23 (39.7) 23 (39.7) 1.000
Dose,  mg/week 8.5  (7.5–30) 8.5 (7.5–30) 1.000
Azathioprine
Current use 19  (32.8) 19 (32.8) 1.000
Dose,  mg/day 62.1 (100–300) 62.1 (100–300) 1.000
Cyclosporine
Current  use 8 (13.8) 8 (13.8) 1.000
Dose,  mg/day 24.1  (100–300) 24.1 (100–300) 1.000
Mycophenolate mofetil
Current  use 2 (3.4) 2 (3.4) 1.000
Dose,  g/day 0.1 (1.5–2.0) 0.1 (1.5–2.0) 1.000
Cyclophosphamide
Current  use 1 (1.7)  1 (1.7) 1.000
Dose  (g/m2 body surface) 1.2 1.2 1.000
Chloroquine  diphosphate
Current  use 9 (15.5) 9 (15.5) 1.000
Dose,  mg/day 250 250 1.000
Leﬂunomide
Current  use 2 (3.4) 2 (3.4) 1.000
Dose,  mg/day 20 20  1.000
Immunosuppressive current use
None 19 (32.8) 19 (32.8) 1.000
One  immunosuppressive 23 (39.7) 23 (39.7) 1.000
Two  immunosuppressive 16 (27.6) 16 (27.6) 1.000
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ofetil (3.4%) and leﬂunomide (3.4%). Twenty-three (39.7%) out of
8 patients were using one immunosuppressive, six (27.6%) were
eceiving two immunosuppressives and 42 (74.1%) were simulta-
eously using immunosuppressive and glucocorticoid therapies.
n addition, 32 (55.2%) patients were using prednisone with a
ean dose at 9.7 mg/day, and nine (15.5%) of them were receiving
0.5 mg/kg/day.
.3. Vaccine immunogenicity in DM/PM patients
The seroconversion rate (p = 0.394), the seroprotection rate
pre- and post-vaccination: p = 0.234 and p = 0.08, respectively), the
MTs (p = 0.932 and p = 0.573) and the factor increases in the GMTs
p = 0.496) were similar in the DM/PM patients and control groups
Table 2).
.4.  The inﬂuence of treatment on the vaccine immune response
The  analysis of the patients’ therapies revealed that DM/PM
atients receiving glucocorticoid treatment had similar serocon-
ersion rates (p = 0.969), seroprotection rates (pre- and post-
accination: p = 0.273 and p = 0.27, respectively), GMTs (p = 0.952
nd p = 0.435) and factor increases in the GMTs (p = 0.403) to
he control group. Likewise, patients receiving a high dose of
lucocorticoid treatment (≥0.5 mg/kg/day) had seroconversion
ates (p = 0.395), seroprotection rates (pre- and post-vaccination:
 = 0.209 and p = 0.667, respectively), GMTs (p = 0.446 and p = 0.292)
nd factor increases in the GMTs (p = 0.501) comparable to
hose of controls. The concomitant use of glucocorticoid and standard deviation (SD). DM,  dermatomyositis; PM,  polymyositis; MMT,  manual
immunosuppressive therapy also resulted in a comparable
immune response to controls [seroconversion rate (p = 0.285), sero-
protection rate (pre- and post-vaccination: p = 0.553 and p = 0.066,
respectively), GMTs (p = 0.786 and p = 0.846) and factor increases in
the GMTs (p = 0.714)], Table 2.
Moreover,  the disease parameters (patients’ VAS, physicians’
VAS, MMT-8, creatine-kinase and aldolase) were comparable
between seroconverted and non-seroconverted patients (p > 0.05)
(data not shown).
3.5.  Adverse events
The  vaccine was well tolerated without any severe adverse
effects during the follow-up. The frequencies of minor local reac-
tions (8.6 vs. 11.2%, p = 0.597) and of mild systemic reactions (15.5
vs. 25.7%, p = 0.123) were similar between the patients and controls.
4. Discussion
To our knowledge, this is the largest study addressing short-
term disease safety of adjuvant-free 2009 inﬂuenza A (H1N1)
vaccine in patients with DM/PM. The vaccine did not seem to have a
deleterious effect on disease and immunoresponse was not affected
by therapy.
The advantages of the present study were the prospec-
tive design and the inclusion of well-deﬁned DM/PM [14]
patients with the careful exclusion of patients with cancer and
other associated-autoimmune diseases. In addition, the patients
were age- and gender-matched with the control group because
S.K. Shinjo et al. / Vaccine 31 (2012) 202– 206 205
Table 2
Serological data before and after inﬂuenza H1N1/2009 vaccine in controls and dermatomyositis/polymyositis patients.
Subset Pre-vaccination Post-vaccination Factor increase Seroconversion
GMT  Seroprotection GMT  Seroprotection
Controls (n = 116) 8.9 (7.7–10.3) 10.3 (4.8–15.9) 102.8 (82.8–127.8) 84.5 (77.9–91.1) 11.6 (9.3–14.4) 78.4 (70.9–86.0)
DM/PM (n = 58) 8.8 (6.9–11.1) 17.2 (7.4–27.0) 119.0 (75.3–188.1) 72.4 (60.8–84.0) 13.6 (9.1–20.3) 72.4 (60.8–84.0)
Using GC (n = 32) 9.0 (7.0–11.5) 18.8 (8.5–29.0) 135.3 (83.7–218.7) 75.0 (63.7–86.3) 15.1 (9.9–23.0) 78.1 (67.3–88.9)
Using GC >0.5 mg/kg/day (n = 9) 12.6 (9.0–17.6) 33.3  (20.5–46.2) 201.6  (127.9–317.7) 77.8 (66.4–89.1) 16.0 (11.3–22.6) 88.9 (80.3–97.5)
Using IS and GC (n = 43) 8.5  (6.8–10.7) 14.0 (4.9–23.0) 109.1 (67.7–175.9) 69.8 (57.8–81.7) 12.8 (8.4–19.6) 69.8 (57.8–81.7)
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[ata are expressed in percentages or value (95% CI). DM, dermatomyositis; facto
mmunosuppressive; PM,  polymyositis.
ll subsets vs. with control group showed p > 0.05.
mmunogenicity varies according to age [13] and gender [20].
e also choose the non-adjuvanted preparation to minimize the
otential risk of ﬂares of underlying autoimmune diseases and the
isk of “adjuvant disease” in genetically susceptible individuals [21]
s deﬁned as autoimmune syndrome induced by adjuvants (ASIA
yndrome) [22,23].
We  have established the disease safety of the pandemic H1N1
nﬂuenza vaccine on the basis of the result that muscle enzymes
nd DM/PM scores remained stable throughout the study; muscle
nzymes and DM/PM scores are well-known indicators of myositis
ctivity in the clinical management of these idiopathic inﬂamma-
ory myopathies [16–19].
Additionally,  we have conﬁrmed our previous ﬁnding that the
eroconversion of the H1N1 pandemic vaccine is adequate and
omparable in age-matched healthy controls in contrast to the
educed vaccine response in patients with juvenile autoimmune
heumatic diseases [24], systemic lupus erythematosus [25] and
heumatoid arthritis [7,26]. One possible explanation for this dis-
repancy is the fact that the majority of the patients were stable
ith respect to laboratory and clinical parameters. Notably, the
eroconversion rate was  also not affected by glucocorticoid and
mmunosuppressive therapies whereas a deleterious effect of these
rugs was reported in patients with systemic lupus erythemato-
us [8], rheumatoid arthritis [7,26], ankylosing spondylitis [7] and
ediatric rheumatic diseases [24].
We further demonstrated that post-vaccination seroprotection
n DM/PM patients was  in fact similar to that in controls when
ompared to a rigorously gender- and age-matched group. The
on-attendance for each subgroup analyzed in our previous study
valuating a large cohort of rheumatic disease patients may  explain
he reduced response reported for DM patients [14].
No  serious short-term adverse events were observed, as
eported previously in patients with autoimmune rheumatic dis-
ase who received seasonal inﬂuenza [7] and pandemic vaccines
8,24–26]. Long term effects on DM/PM could not be ruled out on
he basis of the data presented because of the limited observation
eriod of this study. This result should be interpreted with caution
ecause the overall number of DM/PM patients was  relatively small
o detect relatively infrequent adverse events.
In summary, our data support the administration of the pan-
emic unadjuvanted inﬂuenza A H1N1 2009 vaccine in DM/PM
atients on the basis of our ﬁndings of no short-term harmful effects
elated to the disease itself and the adequate immunogenicity of the
accine in spite of therapy.
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